Download to read offline
Uploaded byUKinItaly
UK-Italy dementia workshop, January 2018 - Nick Fox
The UK Dementia Research Institute (UK DRI) was established with £250 million in joint funding from the MRC, Alzheimer's Society, and Alzheimer's Research UK to accelerate dementia research in the UK. The UK DRI brings together over 300 researchers across 5 centers at universities in Cambridge, Cardiff, Edinburgh, Imperial, Kings College London, and a hub at UCL. It aims to invigorate the therapeutic pipeline for dementias by focusing on innovative discovery science, attracting new talent, and fostering collaboration between research groups through sustained funding, sharing of resources, and an integrated research environment.
More Related Content
Similar to UK-Italy dementia workshop, January 2018 - Nick Fox
UK-Italy dementia workshop, January 2018 - Nick Fox
- 1. ukdri.ac.uk UK DRI Nick Fox Professorof Neurology Dementia Research Centre UK Dementia Research Institute UCL Institute of Neurology Bart De Strooper UK DRI Director Adrian J. Ivinson UK DRI COO
- 2. The need toaccelerate dementia research • 800,000 with dementia in UK – rising to 1m by 2025 • Now the most common cause of death in the UK • Only major disease with increasing deaths • 1 in 3 of those over 65 will die with dementia • Long disease duration – with loss of independence • Cost to the UK economy 2015 ~ £26bn/y – >£4,000m of healthcare; >£10,000m of social care • ~ £66m spent on research For every £10 in direct costs, the research spend was …
- 3. Societal & politicalimperative to make progress against dementia – to invest • Growing public awareness and lobbying • G8 summit in 2012 • Set target of treatment/cure by 2025 • UK Govt doubled research spend & committed to doubling it again • UK charitable and philanthropic funding increasing even faster – AS and ARUK • 2015 >£35m extra per year for research • How to use this investment effectively? • What are the blocks to progress?
- 4. Barriers to progressinclude • Mismatch between research capacity and demand – Physical infrastructure – Human capacity – Leadership • Key gaps in the research pipeline – Molecular biology of dementia (cf cancer) – Target identification and validation (what industry wants from academic science?) • Lack of strategic coordination and alignment of multi- stakeholder, multi-disciplinary efforts. • Lack of an integrated research environment – Lack of “critical mass” and disease focus – Efforts diffuse
- 5. UK Dementia ResearchInstitute • Joint MRC / Alzheimer’s Society / Alzheimer’s Research UK investment of £250M • Centred around the need for innovative, discovery science mechanisms underlying the dementias • Invigorate the therapeutic pipeline • NB – Dementias and neurodegeneration • Bring together expertise in biomedical, care, prevention and translational research
- 6. DRI: culture, connectionsand collaborations • Attract new talent, fill gaps and strengthen expertise • Sustained funding – not short term • A collaborative approach to increase – interaction between research groups – collaboration between centres – sharing of resources, tools, expertise and knowledge – multidisciplinary approaches • Stimulate research with bio-industry and other UK infrastructure • International connectivity – and collaboration
- 7. Structure • The successof the UK DRI depends on the people in it. The institute is structured so that its researchers are connected, wherever their labs are based. • Our hub and 5 centres were selected in open competition – they specialise in certain areas but work together as a single institute. • Ideas, tools, technologies and research data flow between all UK DRI teams. 8
- 8. ukdri.ac.uk UCL: Assoc.Dir. BartDe Strooper • Prof. Nick Fox • Prof. John Hardy • Prof. Gipi Schiavo • Prof. Paul Whiting • Prof. Henrik Zetterberg • Prof. Gill Bates and Prof Sara Tabrizi • Fellows Rita Guerreiro/Jose Bras • Fellow Carlo Frigerio • Fellow Adrian Isaacs Cambridge: Assoc.Dir. Giovanna Malucci • Prof. David Rubinsztein • Prof. David Klenerman Kings: Assoc.Dir. Chris Shaw • Prof. Annalisa Pastore • Sarah Mizielinska Cardiff: Assoc.Dir. Julie Williams • Prof. Philip Taylor • Prof. Paul Morgan • Prof. Valentina Escott-Price • Momentum Awardee: Gaynor Smith • Momentum Awardee: Owen Peters Edinburgh: Assoc.Dir. Giles Hardingham • Prof. Joanna Wardlaw • Prof. Siddharthan Chandran • Fellow Tara Spires-Jones • Fellow Barry McColl • Momentum Awardee Josef Priller Imperial: Assoc.Dir. Paul Matthews • Prof. Paul Elliott • Prof. Elaine Holmes • Prof. William Wisden • Fellow: Nir Grossman Founding Faculty
- 9.
Editor's Notes
- #8 PD: To improve this design- is there another version?
- #10 Adrian’s outline for Bart: High level aims of the DRI: There is strength in neuro and dementia research in the UK, but there are important gaps; DRI will focus on basic molec and cell biol of dementia; with attention to translational opportunities; emerging research themes; the care research agenda’s technology focus; and our ambition to be THE place in the world to deliver a better understanding of dementia and how to prevent it. [ from Adrian ] CM’s additional guidance to Bart: Broad topic areas of the science programmes (second slide on Founding Faculty) Development of cross UK DRI themes (referred to in the last slide) - a good way to emphasise the connectedness of UK DRI and how this will be fostered (internal comms) [may be some sceptics so this will reassure] To say how recruitment is looking promising (can’t give details on a slide) Maybe mention the ideas for providing aged mouse models (too early for a slide on this because of confidentiality) Partnership – DDF and it looks like the links with NIH have firmed up as Frances Collins has agreed to a DRI reception and NIH lab visits next March – more detail once John Savill has talked with him. Important of course to emphasise care to this audience.